Effects of predictive genetic testing

Effects of predictive genetic testing - S00515-NEPHRO

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00017820

Enrollment

800

Registered

2019-12-30

Start date

2018-03-22

Completion date

Unknown

Last updated

2025-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Genetic risk testing for malignancies (e.g., Breast Cancer 1/2), cardiovascular diseases, coagulation (e.g., thrombophilia), storage disorders (e.g., hemochromatosis), cholesterol, glaucoma, and pharmacogenomic information

Interventions

Group 1: Patients who have undergone genetic risk screening and agreed to participate in the study will be tracked over several years by means of questionnaires on quality of life and effects on furth

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: - Declaration of consent to participate in this study - genetic testing performed

Exclusion criteria

Exclusion criteria: - current pregnancy - Active cancer

Design outcomes

Primary

Measure	Time frame
Quality of life, recorded by means of the SF-36 questionnaire at survey times 0 (=baseline, with consent before notification of results of genetic screening), 3 months, 3 years, 5 years (if necessary 10 years) after testing	—

Secondary

Measure	Time frame
Influence of genetic screening on lifestyle and quality of life, recorded at survey times 0 (=baseline, with consent prior to notification of results of genetic screening), 3 months, 3 years, 5 years (possibly 10 years) after the testing device was used - Lucerne Nutrition Index (LEI), and International Physical Activity Questionnaire (IPAQ) questionnaires - Patient satisfaction with genetic screening using qualitative comments and Likert scale - Influence of genetic screening on smoking habits (Qualitative questions and number of cigarettes / d) - Influence of screening on diagnostic and therapeutic prevention measures (qualitative, non-standardised questionnaire) - Influence on clinical endpoints, such as mortality or cardiovascular events, tumor disease and tumor stage at initial diagnosis (qualitative, non-standardized questionnaire) - Influence of screening on the family of patients (Qualitative and non-standardised questionnaire) - Physician/Patients Reported Genetic Test Usefulness (Qualitative and non-standardised questionnaire)	—

Measure

Time frame

Influence of genetic screening on lifestyle and quality of life, recorded at survey times 0 (=baseline, with consent prior to notification of results of genetic screening), 3 months, 3 years, 5 years (possibly 10 years) after the testing device was used - Lucerne Nutrition Index (LEI), and International Physical Activity Questionnaire (IPAQ) questionnaires - Patient satisfaction with genetic screening using qualitative comments and Likert scale - Influence of genetic screening on smoking habits (Qualitative questions and number of cigarettes / d) - Influence of screening on diagnostic and therapeutic prevention measures (qualitative, non-standardised questionnaire) - Influence on clinical endpoints, such as mortality or cardiovascular events, tumor disease and tumor stage at initial diagnosis (qualitative, non-standardized questionnaire) - Influence of screening on the family of patients (Qualitative and non-standardised questionnaire) - Physician/Patients Reported Genetic Test Usefulness (Qualitative and non-standardised questionnaire)

—

Countries

Germany

Contacts

Public ContactSeverin Schricker

Robert Bosch Krankenhaus

severin.schricker@rbk.de0711/8101-3496

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026